RRx-001, a multi-functional drug used in clinical trials such as NCT02518958, not only can promote M1-TAM phenotype but also can be used as an inhibitor of CD47 on cancer cells and SIRPα on macrophages (229, 230). This evidence concerns the gene SIRPA and cancer.